VNDA Stock Analysis: Buy, Sell, or Hold?
VNDA - Vanda Pharmaceuticals Inc.
$6.12
-0.17 (-2.63%)
▼
5d:
-2.47%
30d:
-15.89%
90d:
-1.37%
BUY
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Smart Money Accumulation
VNDA is down 13.6% this week, but smart money is accumulating calls. Top strike: $8 2026-06-18 with 2,595 OI. Call ratio: 86% View Scanner →
Strength: 10.0/10
Get Alerted When VNDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VNDA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VNDA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VNDA is currently trading at $6.12, which is considered oversold relative to its 30-day fair value range of $6.47 to $7.29.
Technical Outlook: Technically, VNDA is in a downtrend. The price is currently testing key support at $6.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VNDA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.90 (+137.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VNDA is in a downtrend. The price is currently testing key support at $6.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VNDA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.90 (+137.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.47 -
$7.29
Company Quality Score
50/100
(HOLD)
Options IV Signal
34th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 34th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 137.3% below Wall St target ($14.90)
Trading Range Analysis
30-Day Trading Range
$6.47 -
$7.29
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.63
(10.4%)
Support & Resistance Levels
Support Level
$6.15
Resistance Level
$7.74
Current Trend
Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.22
Wall Street Target
$14.90
(+137.3%)
Revenue Growth (YoY)
3.4%
Earnings Growth (YoY)
-95.9%
Profit Margin
-110.0%
Share & Embed Analysis
Last updated: May 18, 2026 1:06 PM ET
Data refreshes hourly during market hours. Next update: 2:06 PM
Data refreshes hourly during market hours. Next update: 2:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VNDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Gunther Birznieks
SELL
42431 shares
2026-03-02
Joakim Wijkstrom
SELL
30800 shares
2026-03-02
Kevin Patrick Moran
SELL
42442 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$242 | 64 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 61 BUY |
